On May 1, the clinical study of inactivated vaccine of Omicron variant covid-19 virus developed by Beijing Institute of biological products of Sinopharm group was officially launched in Hangzhou, and the first dose of vaccination was completed on the same day. This is the world’s first covid-19 virus inactivated vaccine for the Omicron variant to enter clinical trials.
Li Lanjuan, academician of the Chinese Academy of engineering, said that at present, Omicron virus is still a serious threat to personnel’s health, and the research and development of related vaccines is of great significance. The clinical effect of the new vaccine entering the clinical research stage and whether the personnel who have been vaccinated with covid-19 vaccine can continue to be vaccinated need to be further explored and verified through clinical response in stages.
China’s vaccination dose is five times higher than that of the United States
As early as April 26, China’s State Drug Administration officially approved the covid-19 virus inactivated vaccine developed by Kexing holding biology and Sinopharm China biology based on Omicron variant into clinical research to evaluate the safety and immunogenicity of covid-19 virus variant vaccine in various populations.
Affected by this news, there were significant changes in pharmaceutical stocks associated with Sinopharm group. On April 26, China National Medicines Corporation Ltd(600511) straight line raised the limit China National Accord Medicines Corporation Ltd(000028) , Shanghai Shyndec Pharmaceutical Co.Ltd(600420) followed the rise, up 8.31% and 4.77% respectively as of the close.
China Industrial Securities Co.Ltd(601377) pointed out that the proportion of vaccination in China has been increasing, and the work of homologous and heterologous immunization has been continuously promoted. Real world data further demonstrate the important and positive role of vaccines in epidemic prevention and control.
According to the wechat official account of “healthy China”, as of May 1, 2022, 31 provinces (autonomous regions and municipalities directly under the central government) and Xinjiang production and Construction Corps had reported 3.346 billion doses of covid-19 virus vaccine.
Globally, 17 countries have received more than 100 million doses of vaccine. China has the largest vaccination dose in the world, 5.8 times that of the United States and 12.3 times that of Japan, which is a little more than twice the total vaccination dose of the United States, Japan, Germany, France, the United Kingdom, Italy, South Korea and other seven developed countries.
the R & D intensity of vaccine concept shares is 3.86 times that of A-Shares
Since November last year, Omicron has been raging around the world for half a year. With the multi-point spread of the epidemic in China, the pace of covid-19 variant vaccine research and development of many enterprises has also been quietly accelerated. According to the Research Report of Dongguan securities in April, at present, the covid-19 vaccine under research in China is mainly concentrated in the three technical paths of mRNA, recombinant protein and virus vector, and many covid-19 vaccines under research have entered the late stage of clinical practice.
According to the disclosed annual report data, the R & D intensity of vaccine related listed companies continued to increase in 2021. According to the statistics of securities times · databao, the overall R & D expenditure of vaccine concept stocks exceeded 17 billion in 2021, accounting for nearly 8% of revenue. The R & D intensity is 3.86 times the overall level of a shares, an increase of 0.83 percentage points over the previous year The R & D expenditure of four companies, including Shanghai Fosun Pharmaceutical (Group) Co.Ltd(600196) , Joincare Pharmaceutical Group Industry Co.Ltd(600380) , Livzon Pharmaceutical Group Inc(000513) , Changchun High And New Technology Industries (Group) Inc(000661) , exceeded 1 billion yuan.
super 70% vaccine concept stocks performance report
In terms of performance, the performance of vaccine concept stocks in 2021 was generally good. According to the statistics of databao, the net profit of more than 70% concept stocks in 2021 increased year-on-year, of which the net profit of 10 stocks doubled, including Cansino Biologics Inc(688185) , Shandong Sinobioway Biomedicine Co.Ltd(002581) , Chongqing Zhifei Biological Products Co.Ltd(300122) , Chengdu Olymvax Biopharmaceuticals Inc(688319) , Beijing Wantai Biological Pharmacy Enterprise Co.Ltd(603392) , etc.
Cansino Biologics Inc(688185) net profit growth was the highest. The company achieved a profit of 1.914 billion yuan last year, turning losses into profits year-on-year. During the reporting period, the commercialization of the recombinant novel coronavirus vaccine (adenovirus type 5 vector) (trade name: kweisa) had a positive impact on the company’s performance with the conditional listing approval and emergency use authorization of many countries at home and abroad.
Vaccine concept stocks have been adjusted for many times this year, and the current valuation level has further moved down. According to data treasure statistics, as of the closing on April 30, the rolling P / E ratio of more than half of vaccine concept stocks was less than 30 times The rolling P / E ratio of five shares including China National Medicines Corporation Ltd(600511) , Chengdu Kanghua Biological Products Co.Ltd(300841) , Beijing Science Sun Pharmaceutical Co.Ltd(300485) , Chongqing Zhifei Biological Products Co.Ltd(300122) , Joincare Pharmaceutical Group Industry Co.Ltd(600380) is less than 15 times.
Since April, some vaccine concept stocks have obtained northward capital increase. According to the statistics of databao, according to the rough calculation of the average transaction price of the interval, Beijing Wantai Biological Pharmacy Enterprise Co.Ltd(603392) , Chongqing Zhifei Biological Products Co.Ltd(300122) , Shenzhen Kangtai Biological Products Co.Ltd(300601) , Cansino Biologics Inc(688185) and other stocks have obtained northward capital increase of more than 100 million yuan Beijing Wantai Biological Pharmacy Enterprise Co.Ltd(603392) obtained the capital increase from north, with the amount of 1.034 billion yuan ranking first. The company’s net profit in the first quarter of this year was 1.331 billion yuan, an increase of 59.72% month on month.
